- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02494999
A Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants
A Randomized, Double-blind, Parallel-Controlled Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Jiangsu
-
Huai'an, Jiangsu, China, 222300
- Huaiyin District Center for Diseases Control and Prevention
-
Huai'an, Jiangsu, China
- Hongze District Center for Disease Control and Prevention
-
Huai'an, Jiangsu, China
- Lianshui County Center for Disease Control and Prevention
-
Lianyungang, Jiangsu, China
- Guanyun County Center for Disease Control and Prevention
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 42-77 days old on the day of inclusion
- Subjects' legal guardians are able to understand and sign the informed consent
- Subjects' legal guardians can and will comply with the requirements of the protocol
- Subjects with temperature <=37.0°C on axillary setting
Exclusion Criteria for First Vaccination:
- Preterm infants or low birth weight infants
- Any administration history of pneumococcal polysaccharide vaccine or pneumococcal conjugate vaccine
- A medical history of culture-confirmed invasive disease caused by Streptococcus pneumonia
- Subject who has allergic history or serious adverse reaction history after vaccination such as allergies, hives, difficulty in breathing, angioedema or abdominal pain
- Subject with congenital malformation, developmental disorder, genetic defects or severe malnutrition
- Subject with epilepsy, a history of seizures or convulsions, or a family history of mental illness
- Known or suspected immune deficiency or immune suppression
- Diagnosed coagulation abnormalities (such as clotting factor deficiency, coagulation disorders, platelet disorder) or significant bruising or blood clotting disorder
- Had immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (not including allergic rhinitis corticosteroid spray treatment, acute uncomplicated dermatitis surfaces corticosteroid therapy) in the past 6 months
- Any prior administration of blood products in last 3 months
- Any prior administration of any attenuated live vaccine in last 14 days
- Any prior administration of subunit or inactivated vaccines in last 7 days
- Any acute infection or serious infection needing systemic antibiotics or antiviral treatment in last 7 days
- Any fever with temperature >=38.0°C on axillary setting in last 3 days
- Any other factors judged by investigator, that may interfere subject's compliance with the protocol
Exclusion Criteria for Second/Third and Booster Vaccination:
If one of the following (1) to (3) adverse events (AE) occurs, further vaccination is prohibited, but other study steps can be continued according to the judgment of the investigators; If one of the following (4) to (5) adverse events occurs, the investigator shall determine whether to continue the following vaccination. In the event of one of the following adverse events (6) to (7), vaccination may be postponed within the time window specified in the protocol.
- (1)The subjects have suffered from severe adverse events caused by the previous vaccination.
- (2)The subjects suffered from severe allergic reactions or hypersensitivity after the previous vaccination.
- (3)Known or suspected autoimmune diseases or immunodeficiency diseases,including HIV infection.
- (4)The occurrence of acute or emerging chronic diseases at the time of vaccination.
- (5)Other reactions (including severe pain, severe swelling, severe restriction of movement, persistent high fever, severe headache, or other systemic or local reactions) judged by the investigators.
- (6)Acute illness (acute illness refers to moderate or severe illness with or without fever) at the time of vaccination.
- (7)The axillary temperature >37.0℃ at the time of vaccination.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 13-valent pneumococcal conjugate vaccine
Single 0.5 ml dose will be given via intramuscular injection in Month 0,2,4 and 10
|
0.5ml vaccine produced by Beijing Minhai Biotechnology Co., Ltd.,three doses with 2 month interval, a booster dose 10 months after the first dose
|
Active Comparator: Prevnar 13
Single 0.5 ml dose will be given via intramuscular injection in Month 0,2,4 and 10
|
0.5ml vaccine produced by Wyeth,three doses with 2 month interval, a booster dose 10 months after the first dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects with serotype-specific pneumococcal IgG antibody concentration ≥ 0.35 ug/mL 30 days after primary vaccination
Time Frame: 30 days after primary vaccination
|
Proportion of subjects with serotype-specific pneumococcal IgG antibody concentration ≥ 0.35 ug/mL 30 days after primary vaccination
|
30 days after primary vaccination
|
Geometric mean concentration (GMC) of serotype-specific pneumococcal IgG antibody 30 days after primary vaccination
Time Frame: 30 days after primary vaccination
|
Geometric mean concentration (GMC) of serotype-specific pneumococcal IgG antibody 30 days after primary vaccination
|
30 days after primary vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects with serotype-specific pneumococcal IgG antibody concentration ≥ 1.0 ug/mL 30 days after primary vaccination
Time Frame: 30 days after primary vaccination
|
Proportion of subjects with serotype-specific pneumococcal IgG antibody concentration ≥ 1.0 ug/mL 30 days after primary vaccination
|
30 days after primary vaccination
|
Geometric mean fold increase (GMI) of serotype-specific pneumococcal IgG antibody 30 days after primary vaccination
Time Frame: 30 days after primary vaccination
|
Geometric mean fold increase (GMI) of serotype-specific pneumococcal IgG antibody 30 days after primary vaccination
|
30 days after primary vaccination
|
Proportion of subjects with serotype-specific geometric mean titer measured by OPA ≥1:8 30 days after primary vaccination
Time Frame: 30 days after primary vaccination
|
Proportion of subjects with serotype-specific geometric mean titer measured by OPA ≥1:8 30 days after primary vaccination
|
30 days after primary vaccination
|
Geometric mean titer (GMT) of serotype-specific pneumococcal IgG antibody measured by OPA 30 days after primary vaccination
Time Frame: 30 days after primary vaccination
|
Geometric mean titer (GMT) of serotype-specific pneumococcal IgG antibody measured by OPA 30 days after primary vaccination
|
30 days after primary vaccination
|
Proportion of subjects with serotype-specific pneumococcal IgG antibody concentration ≥ 0.35 ug/mL 30 days after booster vaccination
Time Frame: 30 days after booster vaccination
|
Proportion of subjects with serotype-specific pneumococcal IgG antibody concentration ≥ 0.35 ug/mL 30 days after booster vaccination
|
30 days after booster vaccination
|
Proportion of subjects with serotype-specific pneumococcal IgG antibody concentration ≥ 1.0 ug/mL 30 days after booster vaccination
Time Frame: 30 days after booster vaccination
|
Proportion of subjects with serotype-specific pneumococcal IgG antibody concentration ≥ 1.0 ug/mL 30 days after booster vaccination
|
30 days after booster vaccination
|
Geometric mean concentration (GMC) of serotype-specific pneumococcal IgG antibody 30 days after booster vaccination
Time Frame: 30 days after booster vaccination
|
Geometric mean concentration (GMC) of serotype-specific pneumococcal IgG antibody 30 days after booster vaccination
|
30 days after booster vaccination
|
Proportion of subjects with serotype-specific geometric mean titer measured by OPA ≥1:8 30 days after booster vaccination
Time Frame: 30 days after booster vaccination
|
Proportion of subjects with serotype-specific geometric mean titer measured by OPA ≥1:8 30 days after booster vaccination
|
30 days after booster vaccination
|
Geometric mean titer (GMT) of serotype-specific pneumococcal IgG antibody measured by OPA 30 days after booster vaccination
Time Frame: 30 days after booster vaccination
|
Geometric mean titer (GMT) of serotype-specific pneumococcal IgG antibody measured by OPA 30 days after booster vaccination
|
30 days after booster vaccination
|
Incidence of adverse reactions (including systemic and local adverse reaction) 30 days after each dose of vaccination
Time Frame: 30 days after each dose of vaccination
|
Incidence of adverse reactions (including systemic and local adverse reaction) 30 days after each dose of vaccination
|
30 days after each dose of vaccination
|
Incidence of severe adverse event (SAE) within 6 months after the first doseof vaccination
Time Frame: 6 months after the first doseof vaccination
|
Incidence of severe adverse event (SAE) within 6 months after the first doseof vaccination
|
6 months after the first doseof vaccination
|
Incidence of severe adverse event (SAE) 30 days after booster vaccination
Time Frame: 30 days after booster vaccination
|
Incidence of severe adverse event (SAE) 30 days after booster vaccination
|
30 days after booster vaccination
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Yuemei Hu, Jiangsu Provincial Centre for Disease Control and Prevention
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- JSVCT022
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pneumonia
-
King Edward Memorial HospitalCompletedNosocomial Pneumonia | Healthcare-Associated Pneumonia | Aspiration Pneumonia | Ventilator-Associated PneumoniaIndia
-
Melinta Therapeutics, Inc.WithdrawnHospital-Acquired Bacterial Pneumonia | Ventilator-Associated Bacterial Pneumonia | Hospital-Acquired Pneumonia | Ventilator-Associated Pneumonia
-
Venatorx Pharmaceuticals, Inc.Department of Health and Human ServicesNot yet recruitingHospital-acquired Pneumonia | Ventilator-associated Pneumonia
-
Hannover Medical SchoolCharite University, Berlin, Germany; University of LeipzigUnknownCOVID-19 | Bacterial Pneumonia | Viral Pneumonia | Pneumonia Due to Streptococcus Pneumoniae | Pneumonia Due to H. Influenzae | Pneumonia, Organism Unspecified | Pneumonia in Diseases Classified Elsewhere | Pneumonia Due to Other Specified Infectious OrganismsGermany
-
Nantes University HospitalSociété Française d'Anesthésie et de RéanimationCompletedPneumonia | Sepsis | Ventilator-Associated Pneumonia | Hospital Acquired PneumoniaFrance
-
PfizerCompletedVentilator-associated Pneumonia (VAP) | Nosocomial Pneumonia (NP)Bulgaria, France, Italy, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, Spain, Turkey, United Kingdom, Vietnam, Philippines, China, Ukraine, Argentina, Brazil, Hungary, Romania, India, Japan, Taiwan, Latvia, Czechia, Slov... and more
-
Arpida AGTerminatedHospital-Acquired Pneumonia | Ventilator-Associated Pneumonia | Health-Care-Associated Pneumonia
-
University Medical Centre LjubljanaUniversity of Ljubljana, Faculty of MedicineUnknownCommunity Acquired Pneumonia | Ventilator Associated Pneumonia | Hospital Acquired PneumoniaSlovenia
-
ShionogiCompletedHospital Acquired Pneumonia (HAP) | Healthcare-associated Pneumonia (HCAP) | Ventilator Associated Pneumonia (VAP)Israel, Spain, United States, Belgium, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Japan, Latvia, Philippines, Puerto Rico, Russian Federation, Serbia, Taiwan, Ukraine
-
Methodist Health SystemCompletedHospital-acquired Pneumonia | Ventilator-associated PneumoniaUnited States
Clinical Trials on 13-valent pneumococcal conjugate vaccine
-
Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdRecruitingConsistency, Immunogenicity, and Safety of Three Batches of 15-valent Pneumococcal Conjugate VaccineHealthy VolunteersChina
-
Sinovac Life Sciences Co., Ltd.RecruitingPneumococcal InfectionsChina
-
Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdNot yet recruiting
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedPneumococcal VaccineKorea, Republic of
-
Murdoch Childrens Research InstituteNational Health and Medical Research Council, Australia; GlaxoSmithKline; Bill... and other collaboratorsCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedVaccines, PneumococcalGermany
-
CanSino Biologics Inc.Henan Center for Disease Control and PreventionCompletedPneumococcal Infections | Bacterial Infections | Streptococcal InfectionsChina
-
Telethon Kids InstitutePapua New Guinea Institute of Medical ResearchCompleted
-
PfizerCompletedPneumococcal DiseaseSpain, Poland, Hungary
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedVaccines, PneumococcalSpain